Literature DB >> 1470228

Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.

J Schneider1, E Beck, C Heers, C Conrad, D de Chaffoy de Courcelles, B Wilffert, T Peters.   

Abstract

R 79595 (N-cyclohexyl-N-methyl-2-[[[phenyl (1,2,3,5-tetrahydro-2 oxoimidazo [2,1-b]-quinazolin-7-yl) methylene] amin] oxy] acetamide) and its isomers represent a novel class of compounds with phosphodiesterase (PDE) inhibitory and cardiotonic (positive inotropic) actions. The cardiac effects of this class of compounds were investigated in the hexobarbital-depressed heart-lung preparation of the guinea-pig. After induction of heart failure (reduction of cardiac output to 25% of the initial value) cumulative addition of R 79595 or its isomers R 80122 (E-isomer) and R 80123 (Z-isomer) concentration-dependently reversed the cardiac depressant effects of hexobarbitone-Na. With regard to reconstitution of contractility and cardiac function R 80122 (E-isomer) was 10 fold more potent than R 79595 (1:1 mixture of the isomers) and nearly 100 fold more potent than R 80123 (Z-isomer). Furthermore, the cardiotonic action of the most potent isomer (R 80122) was compared to the effects of several positive inotropic reference compounds. The order of cardiotonic potency was as follows: (-)-adrenaline > R 80122 = adibendan > digitoxin > milrinone = enoximone > theophylline. Adibendan (EC50 value: 6.7 +/- 1.8 x 10.-8 mol/l), which showed cardiotonic effects in the same concentration range as R 80122 (EC50 value: 6.1 +/- 1.3 x 10(-8) mol/l), was significantly (p < 0.01) less effective than R 80122 with respect to the maximally induceable increase in cardiac output (CO). The cardiotonic effects of R 80122 could be observed in the low concentration range of 3 x 10(-8) to 1 x 10(-6) mol/l, whereas enoximone (EC50 value: 1.2 +/- 0.1 x 10(-5) mol/l) and milrinone (EC50 value: 8.9 +/- 3.5 x 10(-6) mol/l) elicited positive inotropic effects at 100 fold higher concentrations. Digitoxin was 10 fold less and theophylline was 300 fold less potent than R 80122 with regard to reconstitution of heart function. The cardiotonic effects of R 80122 were not accompanied by an increase in heart rate as found with milrinone, theophylline or (-)-adrenaline in this model. Furthermore, the PDE inhibitory effect of R 79595 and its E-isomer R 80122 were investigated in partially purified isoenzymes from guinea-pig ventricles. The IC50 values of R 79595 and R 80122 on PDE I-IV were compared to the IC50 values of adibendan, milrinone, enoximone and theophylline. The selectivity of an inhibitor for PDE III was evaluated by division of its IC50 values on PDE I, II and IV by the IC50 value on PDE III. R 80122 was the most potent and selective PDE III inhibitor.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1470228     DOI: 10.1007/bf00169014

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts.

Authors:  T Bethke; A Klimkiewicz; C Kohl; H von der Leyen; H Mehl; U Mende; W Meyer; J Neumann; W Schmitz; H Scholz
Journal:  J Cardiovasc Pharmacol       Date:  1991-09       Impact factor: 3.105

Review 2.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

3.  Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.

Authors:  R E Weishaar; S D Burrows; D C Kobylarz; M M Quade; D B Evans
Journal:  Biochem Pharmacol       Date:  1986-03-01       Impact factor: 5.858

Review 4.  [Evaluation of heart contractility].

Authors:  C Morgenstern; H Goebel; W Lochner
Journal:  Dtsch Med Wochenschr       Date:  1972-10-13       Impact factor: 0.628

Review 5.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1.

Authors:  W S Colucci; R F Wright; E Braunwald
Journal:  N Engl J Med       Date:  1986-01-30       Impact factor: 91.245

6.  The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.

Authors:  M L Reeves; B K Leigh; P J England
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

7.  Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.

Authors:  D Brunkhorst; H v der Leyen; W Meyer; R Nigbur; C Schmidt-Schumacher; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

8.  Subclasses of cyclic AMP phosphodiesterase in cardiac muscle.

Authors:  R E Weishaar; D C Kobylarz-Singer; H R Kaplan
Journal:  J Mol Cell Cardiol       Date:  1987-10       Impact factor: 5.000

9.  A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.

Authors:  R DiBianco; R Shabetai; W Kostuk; J Moran; R C Schlant; R Wright
Journal:  N Engl J Med       Date:  1989-03-16       Impact factor: 91.245

10.  [Enoximone in postoperative "low-output syndrome"--comparison with dobutamine].

Authors:  L Orellano; M Darwisch; H A Dieterich; V Köllner
Journal:  Z Kardiol       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.